The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
about
Treatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptDefining response to anti-VEGF therapies in neovascular AMDAflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panelDisease severity in newly diagnosed glaucoma patients with visual field loss: trends from more than a decade of data.Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of dataI-Maculaweb: A Tool to Support Data Reuse in Ophthalmology.Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesEfficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysisTwo-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United KingdomThe cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.The Chronic Care for Wet Age Related Macular Degeneration (CHARMED) Study: A Randomized Controlled Trial.Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab InjectionTreatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting.Optical Coherence Tomography in the UK Biobank Study - Rapid Automated Analysis of Retinal Thickness for Large Population-Based StudiesA retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK.Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomesKilovoltage radiosurgery with gold nanoparticles for neovascular age-related macular degeneration (AMD): a Monte Carlo evaluation.GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration.Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration.Ranibizumab for the treatment of wet AMD: a summary of real-world studies.Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration.One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.Assessment of visual distortions in age-related macular degeneration: emergence of new approaches.Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements.A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care.UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections.Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK.A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma.Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials.Response to 'Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.'.Big Data and Uveitis.Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia.
P2860
Q26786766-A97F68B5-3C97-4493-B110-11E740BB4733Q26996510-CE11F367-AB07-44FB-8CFE-F450A1ADED38Q26999836-11D22CA5-131F-4128-A4BB-71BFB5619EAEQ30882123-5FE8235E-1DB1-4BEE-BBEA-AF243CA612BFQ30990445-CE6EBDD3-205F-49CD-8C32-BDAC69F4A6A9Q31095589-F5A2206E-C60A-42DC-A40D-BAFDC49388E1Q33825687-8A2BAB5F-4717-4CDA-90B8-77B8A4A64ED6Q33840787-073A5E05-CA88-4905-B197-49C7031C4576Q33910289-27D15C0F-3F2D-489E-80B4-D18F2634F7FEQ35196822-0581D301-4F39-4D09-9E34-BD2B17F8D74BQ35196853-F267090D-8A54-4C97-BBF2-96D13B842CA5Q35604653-27D2EF1C-D4C5-4F48-8560-ACAFE2A848F6Q35841740-5C571F8F-F7DE-4876-B5B6-3C099F428AEBQ35897929-579B51F8-4FEE-415F-8A3F-B15D2D92E4CDQ36053791-4B9245AD-CF23-4A50-8532-4D609357B110Q36157730-C59609A3-37BB-41D8-B702-382272A80D4BQ36473604-2BD57A61-521E-4B32-9A3E-4DF8A8D80D2DQ36763595-8645C46D-23B0-4D40-B2BD-0B5E65A6D338Q36803774-4B4CF406-DAB7-4963-82F0-EA74A74DB20BQ37444127-6FF4B308-192B-4682-BD1B-B61EDD7CBED7Q37578627-7388CF82-C8F7-4519-8C1B-FEBFBA42C062Q37699709-7C2BA424-E1AB-418E-ADE2-0DB54CF875F7Q38367104-B66B3F37-8267-4C41-A735-766D00DC1297Q38527401-6CC29297-CFB4-4D7A-9E8F-5DB4E4272B83Q38592591-B5B4E62F-3010-4DA7-8B78-80ADA6F658A8Q38712425-E0CBA8BF-9FF6-463F-90F4-6B22409766BCQ38967707-E63A8BF6-8A98-4680-A200-DE501CF62736Q38975099-A81011C9-06CA-43FC-A3BB-0D14C74F7295Q38979931-AA495D80-A442-4BAA-A915-E090B7F6D3BCQ38996254-19E5ACA7-5ADD-46E0-B172-B29E7821E465Q39285726-2F6B4F65-690F-431E-A4AB-5430F69873BEQ39598982-DFC372C1-296D-4A7A-93D9-9079D2B22FCDQ39876159-05C4965C-A326-4C11-BCC9-1DA2D4FBB5D3Q40783264-67FA94F3-3C27-4C12-9067-38869ED24C0DQ41504310-0843F2CC-D3D8-45A3-AACF-673EF97DD037Q41947480-6D86D871-4CBC-470A-A258-0A2CB0C930EAQ42602540-984041D2-1388-4F4B-B88D-A7A8AB729BE9Q42616968-B262172B-A13A-47DB-A619-327F2FA69ABEQ42734776-1A611F47-349D-4F46-8D11-9D98BB2C71A9Q47124190-51DECDF9-D742-4A9D-9502-6F9744568C6A
P2860
The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The neovascular age-related ma ...... ions: report 1: visual acuity.
@en
The neovascular age-related ma ...... ions: report 1: visual acuity.
@nl
type
label
The neovascular age-related ma ...... ions: report 1: visual acuity.
@en
The neovascular age-related ma ...... ions: report 1: visual acuity.
@nl
prefLabel
The neovascular age-related ma ...... ions: report 1: visual acuity.
@en
The neovascular age-related ma ...... ions: report 1: visual acuity.
@nl
P1433
P1476
The neovascular age-related ma ...... ions: report 1: visual acuity.
@en
P2093
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
P304
P356
10.1016/J.OPHTHA.2013.11.031
P577
2014-01-23T00:00:00Z